Skip to content

Type 1 diabetes — beta-cell replacement

TL;DR — Replacement can restore endogenous glucose-responsive insulin secretion, but current approaches trade diabetes risk for surgery, donor scarcity, and immunosuppression. Standardized deceased-donor islet transplantation achieved HbA1c <7% without severe hypoglycemia in 87.5% at one year and 71% at two years among 48 highly selected adults, while renal function fell and procedural bleeding and infection occurred (Hering 2016, PMID 27208344). Stem-cell-derived fully differentiated islets removed donor scarcity in principle: zimislecel engrafted in all 14 early-trial recipients and 10/12 full-dose recipients were insulin-independent at one year, but neutropenia and two deaths occurred under immunosuppression (Reichman 2025, PMID 40544428; NCT04786262). Immunoprotection without systemic immunosuppression is the central unsolved engineering problem.

Replacement options

Modality Cell source/site Can achieve insulin independence? Main constraint
Whole-pancreas transplant Deceased donor; vascularized organ Yes Major surgery and lifelong immunosuppression
Donor-islet transplant Deceased-donor islets; portal vein Sometimes Multiple donors, immunosuppression, attrition
Stem-cell-derived endoderm Renewable progenitors; implant device Low-level function shown Maturation and foreign-body response
Stem-cell-derived mature islets Renewable islets; portal infusion Early insulin independence shown Alloimmunity, autoimmunity, immunosuppression
Encapsulated islets Cells behind immune barrier Not yet established at broad efficacy Oxygen, diffusion, fibrosis, retrieval
Hypoimmune edited cells Gene-edited renewable cells Experimental Immune escape, genomic safety, surveillance

Donor-islet transplantation

The Clinical Islet Transplantation Consortium phase 3 trial enrolled 48 adults with >5 years of T1D, absent stimulated C-peptide, impaired awareness, and severe hypoglycemia despite expert care. The composite of HbA1c <7% plus freedom from severe hypoglycemia was met by 87.5% at one year and 71% at two years; median HbA1c was 5.6% at both times (Hering 2016, PMID 27208344).

Trial safety/outcome Result
Participants 48
Primary endpoint at 1 year 87.5%
Primary endpoint at 2 years 71%
Bleeding requiring transfusion 5/48 (10.4%); 5/75 procedures
Infection attributed to immunosuppression 2/48 (4.1%)
Renal function Significant decline on immunosuppression

Quality-of-life analysis from the same phase 3 program found improvement in health-related outcomes, underscoring that freedom from severe hypoglycemia—not insulin independence alone—is a meaningful goal (Foster 2018, PMID 29563196).

Whole-pancreas transplantation

Whole-pancreas transplantation offers a vascularized β-cell mass and can provide durable insulin independence, most commonly alongside kidney transplantation. Its comparator is not routine insulin therapy but advanced diabetes with renal failure or severe metabolic instability. Operative morbidity, graft thrombosis/rejection, and lifelong immunosuppression limit use.

Choice between pancreas and islet transplantation depends on surgical fitness, kidney status, hypoglycemia burden, local expertise, donor availability, and tolerance of procedural versus graft-function tradeoffs.

Stem-cell proof of function

Implanted pluripotent-stem-cell-derived pancreatic endoderm in a non-immunoprotective device produced fasting and meal-responsive C-peptide; explants contained mature β-cell markers. Fifteen participants at one site were reported, with immunosuppression and without teratoma formation in that early follow-up (Ramzy 2021, PMID 34861146).

Zimislecel uses fully differentiated allogeneic islets infused into the portal vein. In the phase 1–2 interim report, baseline C-peptide was undetectable in all 14; all engrafted, and 10 of 12 full-dose recipients were insulin-independent at day 365. Three had serious neutropenia and two died; the small uncontrolled cohort and concurrent immunosuppression preclude broad safety inference (Reichman 2025, PMID 40544428; NCT04786262).

Zimislecel evidence boundary What is known What is not known
Function Detectable C-peptide in all 14 Durability beyond early follow-up
Independence 10/12 full-dose at one year Population rate in broader stage-3 T1D
Severe hypoglycemia/glycemia Primary composite assessed in full-dose cohort Comparative benefit versus AID
Safety Neutropenia and deaths reported Product-attributable long-term risks
Scale Renewable manufactured source Cost, batch scale, equitable delivery

The immune barrier

Replacement cells face two attacks: alloimmune rejection of donor antigens and recurrence of T1D autoimmunity. Systemic immunosuppression can control both but creates infection, malignancy, renal, hematologic, and drug-toxicity risks. This makes current replacement rational mainly for people whose severe hypoglycemia or transplant context outweighs those risks.

Encapsulation

Encapsulation seeks selective permeability: oxygen, glucose, nutrients, and insulin must cross rapidly, while immune cells and damaging mediators are excluded. Macrodevices are retrievable but diffusion distances and fibrosis constrain cell survival. Microcapsules improve surface area but are harder to retrieve completely.

ClinicalTrials.gov lists VX-264, an encapsulated stem-cell-derived islet program, as active but not recruiting in phase 1/2 (NCT05791201). Registration establishes that the experiment exists, not that immunoprotection works.

Engineering variable Desired property Failure mode
Oxygenation Sustained high flux Central graft hypoxia/necrosis
Glucose-insulin kinetics Minute-scale response Delayed secretion and excursions
Membrane selectivity Immune isolation Cytokine/antibody penetration
Biocompatibility Minimal fibrosis Foreign-body encapsulation
Cell containment No escape Uncontrolled growth or ectopic tissue
Retrieval Complete removal Dispersed or vascularized graft difficult to remove

Hypoimmune editing

Gene editing attempts to reduce immune recognition or add local immune-regulatory signals. The design tension is fundamental: cells invisible to adaptive immunity may also evade infection or tumor surveillance. Required evidence includes genomic integrity, off-target assessment, phenotypic stability, containment, and long-term retrievability.

The live ClinicalTrials.gov recheck on 2026-08-30 identified a two-participant, early-phase-1 intramuscular study of gene-edited hypoimmune human pancreatic islets as recruiting; its registry record was last verified by the sponsor in December 2024 and lists safety as the primary outcome (NCT06239636). Registration confirms a human experiment, not durable immune evasion or clinically sufficient graft function.

Outcomes that matter

  • Freedom from severe hypoglycemia.
  • HbA1c and CGM time in range without clinically important lows.
  • Insulin independence and total daily dose.
  • Stimulated C-peptide and graft-function durability.
  • Kidney function, infection, malignancy, sensitization, and immunosuppressant toxicity.
  • Procedural morbidity and mortality.
  • Quality of life and treatment burden.
  • Manufacturing consistency and cost per durable responder.

Durability of donor-islet outcomes

The Collaborative Islet Transplant Registry analyzed 677 islet-alone or islet-after-kidney recipients. Three-year insulin independence improved from 27% in 1999–2002 to 37% in 2003–2006 and 44% in 2007–2010; severe-hypoglycemia resolution and HbA1c improvement outlasted full insulin independence (Barton 2012, PMID 22723582).

Evidence set Insulin independence Graft function/severe hypoglycemia Boundary
CITR 2007–2010 era 44% at three years C-peptide and severe-event outcomes improved Registry, era confounding
French prospective cohort, n=28 39% at five years; 28% at ten Graft function 82% and 78%; marked severe-event reduction Two or three infusions; immunosuppression
Phase-3 consortium, n=48 Composite 87.5% at one year; 71% at two HbA1c <7% without severe hypoglycemia Highly selected unstable T1D
TRIMECO randomized comparison 64% vs 0% β-score ≥6 at six months Better metabolic outcomes Open label; short randomized comparison

In the 28-person French cohort, primary graft function one month after the last infusion predicted durability; ten-year insulin independence was 28% (95% CI 13–45) and graft function 78% (57–89) (Vantyghem 2019, PMID 31615852). The clinically durable outcome was often protection from severe hypoglycemia rather than complete independence.

Randomized comparison with intensive insulin therapy

TRIMECO randomized 50 adults with severe hypoglycemia/unawareness or poor post-kidney-transplant glycemia to immediate islets or intensive insulin therapy followed by delayed transplant. At six months, 16/25 islet recipients (64%, 95% CI 43–82) versus 0/22 controls (0%, 0–15) achieved modified β-score ≥6 (p<0.0001) (Lablanche 2018, PMID 29776895).

Net benefit included harm: bleeding occurred after 4/55 infusions (7%), and median GFR in recipients without kidney grafts fell from 90.5 to 71.8 mL/min at 12 months. This trial predates current AID performance, so its comparator should now be re-tested.

Immunosuppression and procedure toxicity

Toxicity Evidence Mitigation tension
Portal-infusion bleeding 7% in TRIMECO; 10.4% of phase-3 participants required transfusion Imaging/technique reduce but do not remove risk
Renal decline GFR fell in TRIMECO and long-term cohorts Calcineurin sparing may protect kidney but alter rejection control
Infection/neutropenia Attributed infections in phase 3; neutropenia in cell-replacement trials Less immune suppression risks graft loss
Liver injury Elevated enzymes reported after intraportal procedures Portal site supplies blood but exposes liver
Malignancy/surveillance Long-horizon immunosuppression concern Rare outcomes need registries, not small trials

A nine-person institutional series recorded 16 grade ≥3 adverse events after 17 infusions; 12 were probably/definitely protocol-related, split between early procedure events and later immunosuppressive events (Takita 2012, PMID 22793063). Small-center experience cannot estimate rare-event rates but specifies what must be monitored.

Calcineurin-sparing regimens are not a settled solution. In ten recipients using belatacept- or efalizumab-based approaches, 70% were insulin-independent at ten years, including pancreas-after-islet recipients, but GFR fell from 76.5±23.1 to 50.2±27.1 mL/min and pancreas-after-islet recipients had the largest decline after calcineurin inhibitor initiation (Wisel 2023, PMID 37359825). Efalizumab’s market withdrawal also illustrates dependency on immunosuppressant safety outside diabetes (Posselt 2010, PMID 20659093).

Whole pancreas versus kidney-alone strategies

Successful simultaneous pancreas–kidney transplantation restores renal function and insulin secretion, but intent-to-treat comparisons with living-donor kidney transplantation do not show universal survival superiority. An exploratory synthesis of two comparable studies estimated higher mortality (HR 1.30, 95% CI 1.10–1.54) and kidney-graft failure (HR 1.43, 1.24–1.66) after simultaneous pancreas–kidney versus living-donor kidney transplantation (Bellini 2026, PMID 42646588). Selection, waiting time, perioperative risk, and functional pancreas-graft survival complicate causal inference.

Stem-cell progenitors: function without full replacement

In one report of 17 adults implanted with PEC-01 pancreatic endoderm in vascularized macrodevices, 63% of explanted devices showed engraftment/insulin expression and 6/17 participants had detectable C-peptide by six months. Surgical events comprised 27.9% and immunosuppression effects 33.7% of reported adverse events (Shapiro 2021, PMID 35028608). A companion 15-person site analysis documented meal-responsive C-peptide and mature β-cell markers without teratoma during one-year follow-up (Ramzy 2021, PMID 34861146).

These experiments solved neither immune isolation nor clinically sufficient mass. Their importance was proof that implanted renewable progenitors can mature in humans. Reviews emphasize manufacturing identity, potency, scale, early cell loss, and immune rejection as separate bottlenecks (de Klerk 2021, PMID 33716982; Hogrebe 2023, PMID 37146579).

Stem-cell mature islets: proof and evidence gap

Zimislecel’s 10/12 one-year full-dose insulin independence is a stronger functional signal than progenitor devices, but it remains uncontrolled, immunosuppressed, and early (Reichman 2025, PMID 40544428). Claims of “cure” should therefore specify:

  1. insulin independence versus durable graft survival;
  2. biochemical function versus freedom from severe events;
  3. product effect versus immunosuppressive regimen;
  4. one-year response versus lifetime net benefit;
  5. renewable manufacturing versus affordable delivery.

Encapsulation engineering tradeoffs

Variable Macrodevice advantage Macrodevice cost
Retrieval Localized and removable Limited geometry and foreign-body capsule
Cell containment Stronger physical barrier Lower vascular contact
Oxygen Can incorporate channels/ports Diffusion limits scale with distance squared
Immune isolation Excludes cells Antibodies, cytokines, and nutrients still cross selectively
Monitoring Device can be imaged/explanted Graft function may fail before systemic markers change

Clinical roadmaps warn that hype can outrun the sequential evidence needed for encapsulated stem-cell products: viability, differentiation, glucose responsiveness, adequate dose, immune protection, retrievability, and patient-relevant benefit (Senior 2019, PMID 30362170). Multimodal human pancreatic atlases show the target tissue contains endocrine, exocrine, vascular, stromal, and immune states, so reproducing β cells alone may not reproduce an islet niche (Fasolino 2022, PMID 35228745).

Hypoimmune editing and surveillance

Removing HLA recognition or adding inhibitory ligands may evade alloimmunity, but indirect allorecognition, non-HLA antibodies, recurrent autoimmunity, stress neoantigens, and viral susceptibility remain. First-in-human short-term function without immunosuppression is proof of acute evasion, not lifelong safety (Hassanein 2026, PMID 42626948).

Minimum evidence should include clone-level genomic integrity, off-target and structural-variant assays, residual undifferentiated-cell limits, tumorigenicity testing, viral susceptibility, immune-escape reversibility, a kill switch, and long surveillance with recipient registries.

Outcomes and comparator evolution

Pre-transplant UK candidates reported median 13 severe events/person-year, 90% impaired awareness, impaired diabetes-specific quality of life, and probable anxiety/depression in one quarter (Liew 2020, PMID 32815765). HbA1c did not distinguish psychosocial burden. These data support severe-event and burden endpoints, while also showing how selected the transplant population is.

Because real-world AID now improves TIR by about 11.6 points, transplant trials should compare severe-event elimination, burden, renal function, infection, and quality-adjusted survival against optimized technology—not only historical intensive therapy (Yang 2024, PMID 38888056).

Open questions

  • Can a device sustain a clinically sufficient β-cell mass without systemic immunosuppression? (Ramzy 2021, PMID 34861146; NCT05791201)
  • What is the comparative net benefit of cell replacement versus contemporary AID for severe hypoglycemia? (Hering 2016, PMID 27208344; Brown 2019, PMID 31618560)
  • How durable is zimislecel insulin independence, and how should deaths under immunosuppression be attributed? (Reichman 2025, PMID 40544428)
  • Can edited cells remain immune-protected without losing tumor and infection surveillance? (Hassanein 2026, PMID 42626948; NCT06239636)
  • Which potency assay predicts human graft function before implantation?

References

  1. Hering BJ, et al. Phase 3 Trial of Transplantation of Human Islets in T1D Complicated by Severe Hypoglycemia. Diabetes Care. 2016;39:1230-1240. PMID 27208344
  2. Foster ED, et al. Improved Health-Related Quality of Life in a Phase 3 Islet Transplantation Trial. Diabetes Care. 2018;41:1001-1008. PMID 29563196
  3. Ramzy A, et al. Implanted pluripotent stem-cell-derived pancreatic endoderm cells secrete glucose-responsive C-peptide. Cell Stem Cell. 2021;28:2047-2061.e5. PMID 34861146
  4. Reichman TW, et al. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes. N Engl J Med. 2025;393:858-868. PMID 40544428
  5. Brown SA, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control. N Engl J Med. 2019;381:1707-1717. PMID 31618560
  6. Barton FB, et al. Improvement in outcomes of clinical islet transplantation: 1999-2010. Diabetes Care. 2012;35:1436-1445. PMID 22723582
  7. Vantyghem MC, et al. Ten-Year Outcome of Islet Alone or Islet After Kidney Transplantation. Diabetes Care. 2019;42:2042-2049. PMID 31615852
  8. Lablanche S, et al. Islet transplantation versus insulin therapy: TRIMECO randomized trial. Lancet Diabetes Endocrinol. 2018;6:527-537. PMID 29776895
  9. Takita M, et al. Adverse events in clinical islet transplantation. Cell Transplant. 2012;21:547-551. PMID 22793063
  10. Wisel SA, et al. Calcineurin-Sparing Islet and Pancreas Transplantation. Transpl Int. 2023;36:11367. PMID 37359825
  11. Posselt AM, et al. Islet transplantation using an efalizumab-based protocol. Am J Transplant. 2010;10:1870-1880. PMID 20659093
  12. Bellini MI, et al. Simultaneous Pancreas-Kidney Versus Kidney Transplantation Alone. Med Sci (Basel). 2026;14. PMID 42646588
  13. Shapiro AMJ, et al. Insulin expression and C-peptide after stem-cell-derived pancreatic endoderm implantation. Cell Rep Med. 2021;2:100466. PMID 35028608
  14. de Klerk E, Hebrok M. Stem Cell-Based Clinical Trials for Diabetes Mellitus. Front Endocrinol. 2021;12:631463. PMID 33716982
  15. Hogrebe NJ, et al. Developments in stem cell-derived islet replacement therapy. Cell Stem Cell. 2023;30:530-548. PMID 37146579
  16. Senior PA, Pettus JH. Stem cell therapies for Type 1 diabetes: roadmap for clinical trials. Diabet Med. 2019;36:297-307. PMID 30362170
  17. Fasolino M, et al. Single-cell multi-omics analysis of human pancreatic islets in type 1 diabetes. Nat Metab. 2022;4:284-299. PMID 35228745
  18. Hassanein A, et al. Gene-edited hypoimmune islets as a cure for type 1 diabetes. Expert Opin Biol Ther. 2026. PMID 42626948
  19. Liew AY, et al. Pre-transplant psychosocial burden in an integrated national islet transplant program. Islets. 2020;12:21-31. PMID 32815765
  20. Yang Q, et al. Real-world glycaemic outcomes of automated insulin delivery. Diabetes Obes Metab. 2024;26:3753-3763. PMID 38888056
  21. Shapiro AM. Islet transplantation in type 1 diabetes: long-term outcome. Rev Diabet Stud. 2012;9:385-406. PMID 23804275
  22. Gangemi A, et al. Islet transplantation for brittle type 1 diabetes: the UIC protocol. Am J Transplant. 2008;8:1250-1261. PMID 18444920
  23. Bruni A, et al. Islet cell transplantation: recent advances and future challenges. Diabetes Metab Syndr Obes. 2014;7:211-223. PMID 25018643
  24. Cure P, et al. Islet after kidney transplantation: metabolic control and quality of life. Transplantation. 2008;85:801-812. PMID 18360260
  25. Hering BJ, et al. Advances in Cell Replacement Therapies for Diabetes. Diabetes. 2025;74:1068-1077. PMID 40272266